Sandoz announces launch of piperacillin and tazobactam for injection, a generic version of Zosyn

Sandoz anounced the launch of piperacillin and tazobactam for injection, a generic equivalent of Zosyn®, in the US. Piperacillin and tazobactam for injection is an antibacterial treatment indicated for use in adults with certain types of moderate to severe infections caused by piperacillin-resistant, piperacillin/tazobactam susceptible, ß-lactamase producing strains. Don DeGolyer, President of Sandoz Inc said, Sandoz has a long history of global leadership in developing high-quality, affordable anti-infective medicines. The US launch of piperacillin and tazobactam for injection, or generic Zosyn®, further strengthens our portfolio in this key field as well as our commitment to differentiated products, including injectables

According to IMS Health, branded and generic versions of piperacillin and tazobactam for injection had US sales of approximately USD 797 million for the 12 months ending in August 2010. Sandoz is marketing piperacillin and tazobactam for injection in 2.25 g, 3.375 g and 4.5 g vials, the same standard vial strengths marketed for Zosyn®.